Biomedical Engineering Reference
In-Depth Information
d
n
4
y
3
n
g
|
0
Figure 8.9
Attenuation of DSS-induced colitis by the administration of the antisense
MIF/SPG complex. A total of 0.2 mg kg
21
of the antisense MIF/SPG
complex (ASMIF), scramble control DNA/SPG complex (SCMIF), SPG,
or PBS as a control were injected intraperitoneally (i.p.) twice weekly into
mice receiving DSS (n 5 8 per group). (A) Body weights as a percentage
of the initial weight on day 0 are shown. (B) Colon length from the
terminal ileum to the rectum. (C) Endoscopic findings for the colon. (D)
H&E
staining
of
the
colon
(original
magnification 6100).
(E)
The
histological scores were evaluated.
We examined the biological function and the therapeutic effect of SPG as a
new delivery system formed with antisense MIF against colitis. MIF production
in vitro was significantly suppressed by administering the antisense MIF/SPG
complex, which was taken into the CD11b
+
macrophage more effectively than
antisense MIF alone (Figure 8.8). Administration of the antisense MIF/SPG
complex safely and effectively ameliorated the inflammation of the colon in the
DSS-induced colitis model (Figure 8.9). Our results demonstrated the possibility
of a new therapeutic approach, namely administration of the antisense MIF/
SPG complex, for inflammatory bowel disease.
61
8.4 Conclusion
In this review, we have demonstrated that b-1,3-glucans have a novel feature to
complex with polynucleotides, distinguishing them from other polysaccharides.
